Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 14,205 Shares

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 14,205 shares of Twist Bioscience stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75. Following the sale, the insider directly owned 105,141 shares in the company, valued at approximately $9,436,404.75. This trade represents a 11.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dennis Cho also recently made the following trade(s):

• On Monday, June 22nd, Dennis Cho sold 346 shares of Twist Bioscience stock. The shares were sold at an average price of $87.32, for a total value of $30,212.72.
• On Monday, June 8th, Dennis Cho sold 402 shares of Twist Bioscience stock. The shares were sold at an average price of $69.84, for a total value of $28,075.68.

Twist Bioscience Price Performance

Shares of TWST stock opened at $99.84 on Friday. The stock has a 50 day moving average of $67.01 and a two-hundred day moving average of $51.44. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $104.23. The company has a market capitalization of $6.22 billion, a P/E ratio of -75.07 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.66) earnings per share. As a group, equities analysts expect that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of recent research reports. Leerink Partners set a $80.00 price objective on shares of Twist Bioscience in a research note on Friday, May 22nd. Piper Sandler assumed coverage on shares of Twist Bioscience in a research report on Thursday, June 11th. They set an “overweight” rating and a $85.00 target price on the stock. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research note on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday. Finally, Robert W. Baird raised their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and an average price target of $74.60.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. William Blair Investment Management LLC grew its holdings in shares of Twist Bioscience by 43.7% in the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after purchasing an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. boosted its position in Twist Bioscience by 71.1% in the third quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after buying an additional 1,696,377 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in Twist Bioscience by 26.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after buying an additional 1,349,867 shares in the last quarter. Millennium Management LLC grew its stake in Twist Bioscience by 151.5% during the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock worth $50,479,000 after buying an additional 1,080,722 shares during the last quarter. Finally, ARK Investment Management LLC grew its stake in Twist Bioscience by 12.4% during the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after buying an additional 832,687 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.